By Narda G. Robinson, DO, DVM, MS, FAAMA
The manufacturer of a feline-specific, monoclonal antibody (mAB) drug now awaits approval for its canine counterpart. Photo: TatyanaGl/Bigstock
Earlier this year, veterinarians in the United States finally gained access to a synthetic, feline-specific, monoclonal antibody (mAB) drug designed to treat osteoarthritis pain in cats. Administered as a once-monthly injection, frunevetmab binds to a neurotrophin called nerve growth factor (NGF), a protein found in heightened amounts in painful, arthritic joints.1 By keeping NGF from binding to its receptors, frunevetmab limits its ability to issue nociceptive signals to the spinal cord and brain.
For well over a decade, human pharmaceutical companies invested billions of dollars into d...
You’ve landed on a members-only feature.
If you are already a member, please log in below.
Join VPN Plus+ today to get access to this feature and more like:
- Members-only content:
- In-depth case studies
- New protocols
- Detailed practice management strategies
- More from some of your favorite columnists like Patty Khuly and Brennen McKenzie
- Exclusive webinars, roundtables and videos
- And additional benefits including:
- VIP discounts to VetMedTeam online education and VetCE events
- An annual ‘Vet Box’ full of curated products just for you!